Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU eases its controls on COVID-19 vaccine exports

11/26/2021 | 09:01am EST

BRUSSELS (AP) — The European Union said on Friday that it will ease its restrictions on exporting COVID-19 vaccines.

The Commission, the EU's executive arm, said that as of January it will no longer require vaccine producers to request special authorization to export outside the 27-nation bloc.

Earlier this year when vaccines were still in short supply, the EU introduced a mechanism to keep some of the jabs it secured from AstraZeneca, the Anglo-Swedish drug company, from being diverted elsewhere.

The export control system, aimed at making sure large drug companies would respect their contracts, was used by the EU in March, when a shipment of more than a quarter million AstraZeneca vaccines destined for Australia was blocked from leaving.

When the dispute with AstraZeneca broke, the EU was lagging well behind the United States and other countries in COVID-19 vaccinations. According to Stella Kyriakides, the Commissioner for Health, the bloc has now vaccinated over 65% of the total EU population of some 450 million inhabitants.

The EU and AstraZeneca said in September that they reached a deal to end their legal battle over the slow pace of deliveries of the company’s COVID-19 vaccines.

EU commission spokeswoman Dana Spinant said the “transparency of exports” will be ensured by a new monitoring mechanism that will provide the commission with companies' vaccine export data.

Spinant noted that the EU is the biggest global provider of COVID-19 vaccines, with over 1.3 billion doses exported to more than 150 countries.

Amid a new significant uptick in infections in the EU, European Commission President Ursula von der Leyen said vaccinations need to be stepped up further.

“We need to convince more people to get vaccinated," she said. “The good news is that we have enough vaccine doses. By the end of this week, Europe will have delivered 1 billion doses to our member states."

Follow all of AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

All news about ASTRAZENECA PLC
07:00aCORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with H..
04:37aEnhertu granted Priority Review in the US for patients with HER2-positive metastatic br..
03:01aCline Scientific extends collaboration agreement with AstraZeneca
02:40aAstraZeneca's Enhertu Granted Priority Review by US Regulator
02:31aJens Lindberg takes office as CEO of Medivir on January 24
02:23aAstraZeneca-Daiichi Sankyo's Breast Cancer Drug Accepted For Priority Review in US
02:06aProsecution Takes Over Case of 8 Medics Pinned for Misusing Covid-19 Vaccines
01:09aIsrael Reopens Borders To Entry By Foreign Nationals
01/14EMA lists rare spinal condition as side effect of AstraZeneca's COVID-19 shot
01/14European Medicines Agency Asks AstraZeneca, Johnson & Johnson To Add Spinal Inflammatio..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 079 M - -
Net income 2021 2 716 M - -
Net Debt 2021 24 814 M - -
P/E ratio 2021 54,7x
Yield 2021 2,35%
Capitalization 185 B 186 B -
EV / Sales 2021 5,83x
EV / Sales 2022 4,78x
Nbr of Employees 76 100
Free-Float -
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Last Close Price 119,68 $
Average target price 138,50 $
Spread / Average Target 15,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202